<DOC>
	<DOC>NCT02277600</DOC>
	<brief_summary>This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase the systemic exposure of BMS-626529.</brief_summary>
	<brief_title>A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Healthy male and female Nonsmoking subjects Ages 18 to 50 years Inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive Women of childbearing potential Must agree to follow instructions for methods of contraception for the duration of the study plus 34 days posttreatment completion Any history of acute or chronic medical and surgical illness Personal of family history of hemophilia A or B Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>